CN101326181A - 作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物 - Google Patents

作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物 Download PDF

Info

Publication number
CN101326181A
CN101326181A CNA2006800371946A CN200680037194A CN101326181A CN 101326181 A CN101326181 A CN 101326181A CN A2006800371946 A CNA2006800371946 A CN A2006800371946A CN 200680037194 A CN200680037194 A CN 200680037194A CN 101326181 A CN101326181 A CN 101326181A
Authority
CN
China
Prior art keywords
pyridin
imidazo
pyridine
fluorine
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800371946A
Other languages
English (en)
Chinese (zh)
Inventor
伯奈特·米多·琼
席微亚·芳奎那·波
保罗·罗伯特·伊斯特伍德
荷西·艾瓜德·博世
阿瑞札祖·卡都斯·费格拉斯
艾尼斯·卡润可·莫鲁诺
约克伯·恭扎利兹·罗德瑞贵之
瑟吉欧·派瑞德斯·阿帕瑞奇欧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Publication of CN101326181A publication Critical patent/CN101326181A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2006800371946A 2005-10-06 2006-10-05 作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物 Pending CN101326181A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200502433 2005-10-06
ES200502433A ES2274712B1 (es) 2005-10-06 2005-10-06 Nuevos derivados imidazopiridina.

Publications (1)

Publication Number Publication Date
CN101326181A true CN101326181A (zh) 2008-12-17

Family

ID=36295447

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800371946A Pending CN101326181A (zh) 2005-10-06 2006-10-05 作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物

Country Status (18)

Country Link
US (1) US7855202B2 (https=)
EP (1) EP1931666A1 (https=)
JP (1) JP2009510152A (https=)
KR (1) KR20080050475A (https=)
CN (1) CN101326181A (https=)
AR (1) AR055676A1 (https=)
AU (1) AU2006299028A1 (https=)
CA (1) CA2624879A1 (https=)
EC (1) ECSP088343A (https=)
ES (1) ES2274712B1 (https=)
IL (1) IL190336A0 (https=)
NO (1) NO20082121L (https=)
PE (1) PE20070706A1 (https=)
RU (1) RU2008117329A (https=)
TW (1) TW200800985A (https=)
UY (1) UY29836A1 (https=)
WO (1) WO2007039297A1 (https=)
ZA (1) ZA200802588B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103209981A (zh) * 2010-09-10 2013-07-17 盐野义制药株式会社 具有ampk活化作用的杂环稠合咪唑衍生物
CN107406425A (zh) * 2015-02-25 2017-11-28 帕罗生物制药有限公司 作为腺苷A2b受体拮抗剂和褪黑激素MT3受体的配体的2‑氨基吡啶的衍生物

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
PT2294066E (pt) * 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
WO2010133534A1 (en) * 2009-05-19 2010-11-25 Cellzome Limited Bicyclic amino substituted compounds as pi3k inhibitors
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
US20120003329A1 (en) 2010-06-30 2012-01-05 Gilead Sciences, Inc. Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
CA2836487A1 (en) * 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013063221A1 (en) 2011-10-25 2013-05-02 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
EA201400990A1 (ru) 2012-04-06 2015-01-30 Пфайзер Инк. Ингибиторы диацилглицеринацилтрансферазы 2
EP2861596B1 (en) * 2012-06-19 2019-03-20 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2014145852A2 (en) * 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
CN106537128B (zh) 2014-06-09 2021-06-18 生物统计股份有限公司 用于测量分析物的低成本测试条和方法
SMT202300362T1 (it) 2014-09-12 2023-11-13 Biohaven Therapeutics Ltd Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7
CN114859028A (zh) 2016-07-19 2022-08-05 生物统计股份有限公司 使用批量可校准测试条测量分析物的方法和系统
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
JP7227157B2 (ja) 2016-12-29 2023-02-21 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
JP6836693B2 (ja) 2017-09-28 2021-03-03 シーストーン・ファーマスーティカルズ・（スージョウ）・カンパニー・リミテッドＣｓｔｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ （Ｓｕｚｈｏｕ） Ｃｏ．， Ｌｔｄ． Ａ２ａ受容体アンタゴニストとしての縮合環誘導体
PT3792260T (pt) * 2018-05-08 2024-10-02 Nippon Shinyaku Co Ltd Compostos de azabenzimidazol e produtos farmacêuticos
JP2022516969A (ja) 2019-01-08 2022-03-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
BR112022008457A2 (pt) * 2019-11-13 2022-07-26 Nippon Shinyaku Co Ltd Agente terapêutico e agente profilático para distúrbios gastrointestinais funcionais e xerostomia

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309573D0 (en) * 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
KR0151816B1 (ko) * 1994-02-08 1998-10-15 강박광 신규의 치환된 피리딜 이미다졸 유도체 및 그의 제조방법
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
IL136711A0 (en) 1997-12-19 2001-06-14 Amgen Inc Substituted pyridine and pyridazine compounds and their pharmaceutical use
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
DE60001969T2 (de) 1999-08-31 2004-02-05 Vanderbilt University, Nashville Selektive antagonisten von a2b adenosinrezeptoren
EP1255550A2 (en) 2000-02-17 2002-11-13 Cv Therapeutics, Inc. Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
WO2001062233A2 (en) 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
AU5260601A (en) 2000-04-26 2001-11-07 Eisai Co Ltd Medicinal compositions promoting bowel movement
CN1446202A (zh) 2000-08-11 2003-10-01 卫材株式会社 2－氨基吡啶化合物及其作为药物的用途
AU9502601A (en) 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1360286A2 (en) 2000-09-19 2003-11-12 Chiron Corporation Characterization of the gsk-3beta protein and methods of use thereof
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
DK1401837T3 (da) * 2001-06-29 2005-11-07 Cv Therapeutics Inc Purinderivater som A2B-adenosinreceptorantagonister
TWI330183B (https=) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
ATE520694T1 (de) 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
WO2003063800A2 (en) 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
EP1513848A4 (en) 2002-06-12 2005-11-09 Biogen Idec Inc METHOD FOR TREATING ISCHEMIA REPERFUSION INJURIES WITH ADENOSINE RECEPTOR ANTAGONISTS
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
AU2003282726B2 (en) 2002-10-03 2010-10-07 Targegen, Inc. Vasculostatic agents and methods of use thereof
US7468376B2 (en) 2003-02-27 2008-12-23 Palau Pharma, S.A. Pyrazolopyridine derivates
CA2524778C (en) 2003-05-06 2013-01-29 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
KR101222364B1 (ko) 2003-08-25 2013-01-15 트로비스 파마슈티칼스 엘엘씨 치환된 8-헤테로아릴 크산틴
ES2229928B1 (es) * 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en) 2003-10-03 2003-11-05 Chang Lisa C W Pyrimidines substituted in the 2,4,6 positions and their different uses
CA2543644A1 (en) 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
US7449473B2 (en) 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2303776B1 (es) 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103209981A (zh) * 2010-09-10 2013-07-17 盐野义制药株式会社 具有ampk活化作用的杂环稠合咪唑衍生物
CN103209981B (zh) * 2010-09-10 2016-12-28 盐野义制药株式会社 具有ampk活化作用的杂环稠合咪唑衍生物
TWI567072B (zh) * 2010-09-10 2017-01-21 鹽野義製藥股份有限公司 具有ａｍｐｋ活性化作用之雜環稠合咪唑衍生物及其用途
CN107406425A (zh) * 2015-02-25 2017-11-28 帕罗生物制药有限公司 作为腺苷A2b受体拮抗剂和褪黑激素MT3受体的配体的2‑氨基吡啶的衍生物
CN107406425B (zh) * 2015-02-25 2020-06-26 帕罗生物制药有限公司 作为腺苷A2b受体拮抗剂和褪黑激素MT3受体的配体的2-氨基吡啶的衍生物

Also Published As

Publication number Publication date
TW200800985A (en) 2008-01-01
JP2009510152A (ja) 2009-03-12
AR055676A1 (es) 2007-08-29
NO20082121L (no) 2008-07-07
KR20080050475A (ko) 2008-06-05
ECSP088343A (es) 2008-05-30
ES2274712B1 (es) 2008-03-01
ZA200802588B (en) 2009-09-30
US7855202B2 (en) 2010-12-21
UY29836A1 (es) 2007-04-30
EP1931666A1 (en) 2008-06-18
IL190336A0 (en) 2009-09-22
WO2007039297A1 (en) 2007-04-12
US20080275038A1 (en) 2008-11-06
PE20070706A1 (es) 2007-09-24
ES2274712A1 (es) 2007-05-16
RU2008117329A (ru) 2009-11-20
AU2006299028A1 (en) 2007-04-12
CA2624879A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
CN101326181A (zh) 作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物
JP4650419B2 (ja) ピラジン誘導体およびその医薬的使用
CN1942469B (zh) 用作a28腺苷受体拮抗剂的稠合吡啶衍生物
CN101065377B (zh) 咪唑并[1,2-a]吡啶化合物、组合物、与其有关的应用和方法
WO2023051753A1 (zh) 一种rock抑制剂的制备方法、其中间体及中间体的制备方法
CN101336238A (zh) 新颖的二环羰基氨基吡啶-2-甲酰胺或3-二环羰基氨基吡嗪-2-甲酰胺
ES2270715A1 (es) Nuevos derivados de pirazina.
CN101801931A (zh) 作为二氢乳清酸脱氢酶抑制剂的氮杂联苯胺基苯甲酸衍生物
EP2125804B1 (en) 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazo[4,5-b]pyridin-2-one derivatives useful as a2b adenosine receptor antagonists
JPS59141564A (ja) 新規ピリダジン誘導体，その製造方法及び該誘導体を含有する神経系治療剤
CN101495450A (zh) 用于治疗疼痛、胃肠道疾病和癌症的异吲哚衍生物
CN102633812B (zh) 噁唑酮并喹唑啉衍生物、制备方法及用途
MX2014005228A (es) Compuestos farmaceuticos.
JP2005132834A (ja) キノリン誘導体
JP2007532658A (ja) がんの治療方法
CN107721919B (zh) 苯基喹啉类trpv1拮抗剂及其制备方法和应用
WO2015097122A1 (en) Benzene sulfonamides as ccr9 inhibitors
CN103012381A (zh) 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
JP2019501126A5 (https=)
TW201249801A (en) 3-ureidoisoquinolin-8-yl derivatives
ES2234433B1 (es) 4-aminopirimidinas como antagonistas de receptores de adenosina.
JP2023527379A (ja) Ｔｒｅｘ１のモジュレーターとしての置換ベンズアミド
CN109879820A (zh) 一种喹唑啉酮杂环化合物的合成方法
JPS601303B2 (ja) 新規オキシムエ−テル化合物およびその塩類
CN113999205B (zh) 含三氮唑酮酰胺和咪唑酰胺结构的吡啶类化合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20081217